Mode
Text Size
Log in / Sign up
N/A N=125 Single-blind Supportive Care

Lens Wearing Experience and Biocompatibility of a Multi-Purpose Disinfecting Solution (MPDS)

Healthy

Enrolled (actual)
125
Serious AEs
0.0%
Results posted
Nov 2012
Primary outcome: Primary: Corneal Fluorescein Staining Type at Baseline — 1.7 Units on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
OPTI-FREE PureMoist multipurpose disinfecting solution (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Alcon Research
Primary completion
Oct 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
Corneal Fluorescein Staining Type at Baseline
1.7
PRIMARY
Corneal Fluorescein Staining Type at Day 30
0.7
PRIMARY
Corneal Fluorescein Staining Area at Baseline
5.6
PRIMARY
Corneal Fluorescein Staining Area at Day 30
1.4

Summary

The purpose of this study was to evaluate the efficacy of a new multipurpose disinfecting solution in silicone hydrogel and soft contact lens wearers.

Eligibility Criteria

Inclusion Criteria

  • Wear silicone hydrogel or traditional soft contact lenses on a daily wear basis, (a minimum of 8 hours per day) for at least one month prior to Visit 1;
  • Habitual use of a multi-purpose solution containing PHMB for at least 30 days prior to Visit 1;
  • Vision correctable to 20/30 (Snellen) or better in each eye at distance with pre-study lenses at Visit 1;
  • Read, sign, and date IRB-approved informed consent and privacy document;
  • Be generally healthy and have normal ocular health;
  • Willing to follow the study procedures and visit schedule;
  • Other protocol-defined inclusion criteria may apply.

Exclusion Criteria

  • Wear lenses on an extended wear basis during the study;
  • Known sensitivity or intolerance to PHMB, POLYQUAD, or ALDOX preserved lens care products;
  • Monocular subject;
  • Requirestoric or multifocal contact lenses;
  • Use of additional lens care products other than a PHMB multi-purpose solution such as daily or enzyme cleaners within the one week prior to Visit 1;
  • Use of topical ocular over-the-counter (OTC) or prescribed topical ocular medications, with the exception of rewetting drops, within 7 days prior to Visit 1;
  • Any abnormal ocular condition observed during the Visit 1 Slit-lamp examination;
  • Ocular surgery within the 12 months prior to Visit 1;
  • Use of any systemic medication which has known or expected ocular or systemic side effects at Visit 1, that in the clinical judgment of the investigator, could affect the subject's participation in this study;
  • Any systemic disease at Visit 1 that may affect the eye or be exacerabated by use of contact lenses or contact lens solutions or which could prevent subjects from wearing their lenses at least 8 hours per day;
  • Participation in any clinical study within 30 days of Visit 1;
  • Other protocol-defined exclusion criteria may apply.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01476722). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search